

Hemorrhage Therapeutic Pipeline Market Review, H2 2016

*Hemorrhage Treatment Pipeline Review
H2 2016*

PUNE, INDIA, October 14, 2016

/EINPresswire.com/ -- This report

provides comprehensive information on the therapeutic development for [Hemorrhage](#), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhage and special features on late-stage and discontinued projects.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/184885-hemorrhage-pipeline-review-h2-2015>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hemorrhage
- The report reviews key pipeline products under drug profile section which includes, product

description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Hemorrhage and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hemorrhage pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hemorrhage
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hemorrhage pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=184885

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hemorrhage Overview 6

Therapeutics Development 7

Pipeline Products for Hemorrhage - Overview 7
Pipeline Products for Hemorrhage - Comparative Analysis 8
Hemorrhage - Therapeutics under Development by Companies 9
Hemorrhage - Therapeutics under Investigation by Universities/Institutes 10
Hemorrhage - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hemorrhage - Products under Development by Companies 13
Hemorrhage - Products under Investigation by Universities/Institutes 14
Hemorrhage - Companies Involved in Therapeutics Development 15
Cellphire, Inc. 15
Digna Biotech, S.L. 16
Haemostatix Limited 17
QRxPharma Limited 18
Serendex Pharmaceuticals A/S 19
Thrombotargets Europe SL 20
Hemorrhage - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
DB-055 - Drug Profile 30

Access Report @ <https://www.wiseguyreports.com/reports/184885-hemorrhage-pipeline-review-h2-2015>

Follow Us:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/349312769>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.